These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8448975)

  • 1. Aminoglycoside forecasting in neutropenic patients with cancer.
    Kosirog JL; Rospond RM; Destache C; Hall P
    Clin Pharmacokinet; 1993 Jan; 24(1):79-87. PubMed ID: 8448975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as the internal estimates.
    McClellan SD; Farringer JA
    Ther Drug Monit; 1989; 11(4):431-6. PubMed ID: 2741192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patients.
    Radomski KM; Davis GA; Chandler MH
    Am J Health Syst Pharm; 1997 Mar; 54(5):541-4. PubMed ID: 9066862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Evaluation of Gentamicin, Tobramycin, and Amikacin Pharmacokinetic/Pharmacodynamic Parameters in HIV-Infected Children.
    Rodriguez JC; Schoenike S; Scott GB; Rossique-Gonzalez MT; Gomez-Marin O
    J Pediatr Pharmacol Ther; 2003 Oct; 8(4):274-83. PubMed ID: 23118683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients.
    Denaro CP; Ravenscroft PJ
    Aust N Z J Med; 1987 Oct; 17(5):526-32. PubMed ID: 3446165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of aminoglycoside pharmacokinetics in postpartum patients using Bayesian forecasting.
    Cropp CD; Davis GA; Ensom MH
    Ther Drug Monit; 1998 Feb; 20(1):68-72. PubMed ID: 9485558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.
    Grucz TM; Kruer RM; Bernice F; Lipsett PA; Dorman T; Sugrue D; Jarrell AS
    Surg Infect (Larchmt); 2020 Dec; 21(10):859-864. PubMed ID: 32302517
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens.
    Duffull SB; Kirkpatrick CM; Begg EJ
    Br J Clin Pharmacol; 1997 Feb; 43(2):125-35. PubMed ID: 9131944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
    Inparajah M; Wong C; Sibbald C; Boodhan S; Atenafu EG; Naqvi A; Dupuis LL
    Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models.
    Duong A; Marsot A
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):739-747. PubMed ID: 38465725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
    de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
    Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compatibility and stability of clindamycin phosphate-aminoglycoside combinations within polypropylene syringes.
    Zbrozek AS; Marble DA; Bosso JA; Bair JN; Townsend RJ
    Drug Intell Clin Pharm; 1987 Oct; 21(10):806-10. PubMed ID: 3428140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients.
    Denaro CP; Ravenscroft PJ
    Br J Clin Pharmacol; 1989 Jul; 28(1):37-44. PubMed ID: 2775614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of serum concentrations of some aminoglycoside antibiotics by use of the fluorescent immunoassay method.
    Dzierzanowska D; Nowik-Jurek M; Podleśny J
    Arch Immunol Ther Exp (Warsz); 1983; 31(3):389-94. PubMed ID: 6651487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin dosing in neutropenic patients.
    Haeseker MB; Croes S; Neef C; Bruggeman CA; Stolk LM; Verbon A
    PLoS One; 2014; 9(11):e112008. PubMed ID: 25390637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
    Alghanem S; Paterson I; Touw DJ; Thomson AH
    J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients.
    Mareville J; Gay J; Cliquennois E; Herbaux C; Pasquier F; Allorge D; Blondiaux N; Berthon C; Alfandari S
    Scand J Infect Dis; 2012 May; 44(5):398-401. PubMed ID: 22235869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.